ProQR Therapeutics (NASDAQ:PRQR) Earns "Buy" Rating from Chardan Capital
Chardan Capital reiterated a "buy" rating and issued a $4.00 target price on shares of ProQR Therapeutics in a research note on Thursday...
MarketBeat·2d ago
More News
Aberdeen Group plc Has $5.96 Million Holdings in ProQR Therapeutics N.V. $PRQR
Aberdeen Group plc increased its holdings in ProQR Therapeutics N.V. (NASDAQ:PRQR - Free Report) by 28.4% during the fourth quarter, according to its most recent 13F filing with the Securities and...
MarketBeat·2d ago
ProQR Therapeutics Unveils New RNA Editing Programs; AX-0810 Phase 1 Target Data Due This Quarter
ProQR Therapeutics (NASDAQ:PRQR) outlined multiple pipeline updates and development priorities during its virtual investor and analyst event, highlighting upcoming clinical readouts for its lead RNA...
MarketBeat·3d ago
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of "Moderate Buy" by Brokerages
ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eight analysts that are covering the stock, MarketBeat reports. One analyst...
MarketBeat·10d ago
Q2 Earnings Estimate for PRQR Issued By HC Wainwright
ProQR Therapeutics N.V. (NASDAQ:PRQR - Free Report) - Research analysts at HC Wainwright issued their Q2 2026 EPS estimates for shares of ProQR Therapeutics in a report released on Monday, March...
MarketBeat·24d ago
Brokers Issue Forecasts for PRQR Q1 Earnings
ProQR Therapeutics N.V. (NASDAQ:PRQR - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of ProQR Therapeutics in a note issued to...
MarketBeat·25d ago
ProQR Therapeutics (NASDAQ:PRQR) Raised to Hold at Wall Street Zen
Wall Street Zen raised shares of ProQR Therapeutics from a "strong sell" rating to a "hold" rating in a report on Saturday...
ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.09) EPS for the quarter, missing the consensus...
MarketBeat·29d ago
ProQR Therapeutics (NASDAQ:PRQR) Coverage Initiated at Oppenheimer
Oppenheimer started coverage on ProQR Therapeutics in a report on Thursday. They set an "outperform" rating and a $9.00 price objective on the stock...
ProQR (PRQR) delivered earnings and revenue surprises of -12.50% and -36.14%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?